Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) FCF Margin (2021 - 2025)

Historic FCF Margin for Krystal Biotech (KRYS) over the last 4 years, with Q4 2025 value amounting to 70.37%.

  • Krystal Biotech's FCF Margin rose 126000.0% to 70.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 48.55%, marking a year-over-year increase of 89900.0%. This contributed to the annual value of 48.55% for FY2025, which is 89900.0% up from last year.
  • As of Q4 2025, Krystal Biotech's FCF Margin stood at 70.37%, which was up 126000.0% from 38.81% recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's FCF Margin peaked at 822.32% during Q1 2021, and registered a low of 249.31% during Q3 2023.
  • Over the past 4 years, Krystal Biotech's median FCF Margin value was 38.81% (recorded in 2025), while the average stood at 80.27%.
  • In the last 5 years, Krystal Biotech's FCF Margin surged by 3198400bps in 2024 and then plummeted by -317200bps in 2025.
  • Over the past 4 years, Krystal Biotech's FCF Margin (Quarter) stood at 822.32% in 2021, then tumbled by -102bps to 18.81% in 2023, then soared by 407bps to 57.77% in 2024, then rose by 22bps to 70.37% in 2025.
  • Its last three reported values are 70.37% in Q4 2025, 38.81% for Q3 2025, and 52.92% during Q2 2025.